Literature DB >> 23750780

Anti-angiogenic activity of salvicine.

Yanli Zhang1, Lei Wang, Yajuan Chen, Chen Qing.   

Abstract

CONTEXT: Salvicine is a pharmacologically active derivative from Chinese medicinal plant Salvia prionitis Hance (Labiatae). It has been reported that salvicine inactivates β1 integrin and inhibits integrin-mediated cell adhesion to fibronectin. Given the emerging correlation between integrins and angiogenesis, we propose that salvicine abolishes cell adhesion and subsequent metastasis by inhibiting angiogenisis.
OBJECTIVE: The anti-angiogenesis activities of salvicine were investigated for the first time.
MATERIALS AND METHODS: The cytotoxicity of salvicine on human microvascular endothelial cells (HMECs) and non-small cell lung adenocarcinoma A549 cells were measured at doses between 0.625 and 200 µM. Changes of cell migration were detected with doses of salvicine at 1.25-5 µM, and basement membrane matrigel matrix was used for the assessment of tube formation at concentrations ranging from 0.078 to 1.25 µM. In addition, mRNA expression of basic fibroblast growth factor (bFGF) in A549 cells was studied with the RT-PCR assay.
RESULTS: In vitro studies revealed that the IC50 of salvicine on A549 cells (18.66 µM) was two-fold higher than that of HMECs (7.91 µM). Salvicine (1.25, 2.5 and 5.0 μM) inhibited significantly the endothelial cell migration up to 56, 73 and 82%, respectively. Salvicine decreased capillary-like tube formation of HMECs with high potency. Furthermore, it (30 µM) markedly reduced the mRNA expression of bFGF in A549 cells, while vascular endothelial growth factor (VEGF) mRNA expression remained unchanged. DISCUSSION AND
CONCLUSION: Our results suggest that salvicine has potent anti-angiogenic activity through the inhibition on the sequential angiogenic cascades: proliferation, migration and tube formation and is associated with influence on the expression of bFGF of tumor cell.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750780     DOI: 10.3109/13880209.2013.776612

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  3 in total

Review 1.  Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade.

Authors:  Dipta Dey; Mohammad Mehedi Hasan; Partha Biswas; Stavros P Papadakos; Rehab A Rayan; Sabiha Tasnim; Muhammad Bilal; Mohammod Johirul Islam; Farzana Alam Arshe; Efat Muhammad Arshad; Maisha Farzana; Tanjim Ishraq Rahaman; Sumit Kumar Baral; Priyanka Paul; Shabana Bibi; Md Ataur Rahman; Bonglee Kim
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

2.  Computational screening of chalcones acting against topoisomerase IIα and their cytotoxicity towards cancer cell lines.

Authors:  Kanyani Sangpheak; Monika Mueller; Nitchakan Darai; Peter Wolschann; Chonticha Suwattanasophon; Ritbey Ruga; Warinthon Chavasiri; Supaporn Seetaha; Kiattawee Choowongkomon; Nawee Kungwan; Chompoonut Rungnim; Thanyada Rungrotmongkol
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 3.  Quinonoids: Therapeutic Potential for Lung Cancer Treatment.

Authors:  Hua-Zhong Ying; Chen-Huan Yu; Hao-Kun Chen; Huan-Huan Zhang; Jie Fang; Fang Wu; Wen-Ying Yu
Journal:  Biomed Res Int       Date:  2020-04-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.